ES2121180T3 - Sintesis mejorada de conjugados de polimero/sustancia bioactiva. - Google Patents
Sintesis mejorada de conjugados de polimero/sustancia bioactiva.Info
- Publication number
- ES2121180T3 ES2121180T3 ES94902692T ES94902692T ES2121180T3 ES 2121180 T3 ES2121180 T3 ES 2121180T3 ES 94902692 T ES94902692 T ES 94902692T ES 94902692 T ES94902692 T ES 94902692T ES 2121180 T3 ES2121180 T3 ES 2121180T3
- Authority
- ES
- Spain
- Prior art keywords
- poly
- ethylene glycol
- glycoprotein
- protein
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE PRESENTA UN METODO PARA LA PREPARACION DE UN CONJUGADO ENTRE UN POLIMERO Y UNA PRIMERA SUBSTANCIA QUE TIENE UNA ACTIVIDAD BIOLOGICA INTERMEDIADA POR UN DOMINANTE DE LA MISMA, DICHO PROCESO COMPRENDE: A) LA PUESTA EN CONTACTO DE LA PRIMERA SUBSTANCIA CON UNA SEGUNDA SUBSTANCIA QUE ESPECIFICAMENTE SE UNA A DICHO DOMINANTE DE LA PRIMERA SUBSTANCIA B); LA CONJUGACION DE UN POLIMERO CON LA PRIMERA SUBSTANCIA QUE TIENE LA SEGUNDA SUBSTANCIA UNIDA A LA MISMA; Y C) LA LIBERACION DE LA SEGUNDA SUBSTANCIA DE LA PRIMERA SUBSTANCIA QUE TIENE EL POLIMERO CONJUGADO A LA MISMA. SE PRESENTAN CONJUGADOS ENTRE UN POLIMERO Y UN ANTICUERPO CONTRA EL TNF-(ALFA).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929225448A GB9225448D0 (en) | 1992-12-04 | 1992-12-04 | Improved synthesis of polymer bioactive conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2121180T3 true ES2121180T3 (es) | 1998-11-16 |
Family
ID=10726165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94902692T Expired - Lifetime ES2121180T3 (es) | 1992-12-04 | 1993-12-06 | Sintesis mejorada de conjugados de polimero/sustancia bioactiva. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6172202B1 (es) |
EP (1) | EP0675736B1 (es) |
JP (1) | JP3557206B2 (es) |
AT (1) | ATE168273T1 (es) |
AU (1) | AU678796B2 (es) |
CA (1) | CA2150925C (es) |
DE (1) | DE69319740T2 (es) |
DK (1) | DK0675736T3 (es) |
ES (1) | ES2121180T3 (es) |
GB (1) | GB9225448D0 (es) |
WO (1) | WO1994013322A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2064915C (en) * | 1989-08-07 | 2001-05-29 | Deborah A. Rathjen | Tumour necrosis factor binding ligands |
US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
US20030225254A1 (en) * | 1989-08-07 | 2003-12-04 | Rathjen Deborah Ann | Tumour necrosis factor binding ligands |
US20040120952A1 (en) * | 2000-08-07 | 2004-06-24 | Centocor, Inc | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
EP0585705B1 (en) * | 1992-08-28 | 1998-11-04 | Bayer Corporation | Use of monoclonal antibodies to TNF to treat bacterial meningitis |
US20050255104A1 (en) * | 1993-01-29 | 2005-11-17 | Centocor, Inc. | Methods of treating psoriasis using anti-TNF receptor fusion proteins |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6548644B1 (en) * | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
EP1062230B1 (en) * | 1998-03-05 | 2004-10-13 | Chiron Corporation | Method for increasing the serum half-life of a biologically active molecule |
US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
TWI257394B (en) | 1998-10-23 | 2006-07-01 | Kirin Amgen Inc | Thrombopoietic compounds |
DE60045240D1 (de) * | 1999-03-02 | 2010-12-30 | Centocor Inc | Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma |
US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US20050249735A1 (en) * | 2000-08-07 | 2005-11-10 | Centocor, Inc. | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor |
US20110195063A1 (en) * | 2000-08-07 | 2011-08-11 | Centocor, Inc. | Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor |
US20040091602A1 (en) * | 2000-10-04 | 2004-05-13 | Hwang Hyun Jin | Method for immobilizing biologically active molecules |
US7238505B2 (en) | 2000-10-04 | 2007-07-03 | Ahram Biosystems Inc. | Immobilized DNA polymerase |
EP1234583A1 (en) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
SE0104186D0 (sv) * | 2001-12-12 | 2001-12-12 | Darcy Birse | Method and device |
WO2004019991A2 (en) * | 2002-08-30 | 2004-03-11 | F. Hoffmann-La Roche Ag | Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma |
ES2347239T3 (es) * | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
WO2006010057A2 (en) | 2004-07-08 | 2006-01-26 | Amgen Inc. | Therapeutic peptides |
EP2004231A4 (en) | 2006-04-07 | 2013-07-10 | Nektar Therapeutics | CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY |
JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
JP2010528647A (ja) * | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
US20090038182A1 (en) * | 2007-08-09 | 2009-02-12 | Lans Maris J | Footwear with built-in scale |
WO2010045321A2 (en) * | 2008-10-15 | 2010-04-22 | Baxter International Inc. | Pegylation of recombinant blood coagulation factors in the presence of bound antibodies |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863729A (en) * | 1984-06-20 | 1989-09-05 | Linus Pauling Institute Of Science And Medicine | Method for preparing a macromolecular monoclonal antibody composition |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
US5047227A (en) * | 1988-02-08 | 1991-09-10 | Cytogen Corporation | Novel and improved antibodies for site specific attachment of compounds |
US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
JPH02201162A (ja) * | 1989-01-30 | 1990-08-09 | Teijin Ltd | 酵素抗体複合体、複合体―抗体の組合せ、キット及び診断方法 |
GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
DE69217914T2 (de) * | 1991-01-22 | 1997-10-09 | Rover Group | Eine lufteinlassleitung für verbrennungsmotoren |
SE502083C2 (sv) | 1991-05-28 | 1995-08-07 | Misomex Ab | Förfarande och anordning för automatiserad exponering av ljuskänsligt material medelst laserljus |
IT1260468B (it) * | 1992-01-29 | 1996-04-09 | Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole | |
IT1254315B (it) * | 1992-03-27 | 1995-09-14 | Mini Ricerca Scient Tecnolog | Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf. |
US5314830A (en) * | 1992-10-30 | 1994-05-24 | University Of New Mexico | Immobilized hydrophobically-modified antibodies |
US5556623A (en) * | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
-
1992
- 1992-12-04 GB GB929225448A patent/GB9225448D0/en active Pending
-
1993
- 1993-12-06 WO PCT/EP1993/003429 patent/WO1994013322A1/en active IP Right Grant
- 1993-12-06 JP JP51376394A patent/JP3557206B2/ja not_active Expired - Fee Related
- 1993-12-06 DE DE69319740T patent/DE69319740T2/de not_active Expired - Lifetime
- 1993-12-06 AT AT94902692T patent/ATE168273T1/de active
- 1993-12-06 AU AU56968/94A patent/AU678796B2/en not_active Ceased
- 1993-12-06 CA CA002150925A patent/CA2150925C/en not_active Expired - Fee Related
- 1993-12-06 ES ES94902692T patent/ES2121180T3/es not_active Expired - Lifetime
- 1993-12-06 DK DK94902692T patent/DK0675736T3/da active
- 1993-12-06 EP EP94902692A patent/EP0675736B1/en not_active Expired - Lifetime
-
1997
- 1997-07-07 US US08/889,049 patent/US6172202B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU5696894A (en) | 1994-07-04 |
DE69319740T2 (de) | 1999-03-11 |
CA2150925C (en) | 2009-02-03 |
GB9225448D0 (en) | 1993-01-27 |
AU678796B2 (en) | 1997-06-12 |
ATE168273T1 (de) | 1998-08-15 |
DK0675736T3 (da) | 1999-04-19 |
DE69319740D1 (de) | 1998-08-20 |
EP0675736B1 (en) | 1998-07-15 |
CA2150925A1 (en) | 1994-06-23 |
JPH08504202A (ja) | 1996-05-07 |
EP0675736A1 (en) | 1995-10-11 |
WO1994013322A1 (en) | 1994-06-23 |
US6172202B1 (en) | 2001-01-09 |
JP3557206B2 (ja) | 2004-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2121180T3 (es) | Sintesis mejorada de conjugados de polimero/sustancia bioactiva. | |
PT1028753E (pt) | Libertacao de moleculas de poli(etilenoglicol)-conjugado a partir de hidrogeles degradaveis | |
DE60006100D1 (de) | Lang wirkende insulinotrope peptide | |
CA2323048A1 (en) | Poly(ethylene glycol) derivatives with proximal reactive groups | |
CA2316834A1 (en) | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom | |
WO2000061788A3 (en) | Poly(dipeptide) as a drug carrier | |
ES2182908T3 (es) | Nuevos peptidos. | |
IE861706L (en) | Solubilization of proteins for pharmaceutical compositions¹using polymer conjugation | |
DE60141992D1 (es) | ||
YU21399A (sh) | Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže | |
ATE214610T1 (de) | Neuartige pharmazeutische verwendungen von krill- enzymen | |
ZA927360B (en) | Improved tissue glue prepared by using cryoprecipitate | |
NZ506631A (en) | Formulations for the stabilisation of PEG-interferon alpha conjugates during and after lyophilization | |
AU639257B2 (en) | Proteins having anticoagulant properties | |
PT830130E (pt) | Enzima de conversao de tnf-alfa | |
WO2000070665A3 (en) | Long lasting anti-angiogenic peptides | |
PT1150716E (pt) | Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao | |
ES2170161T3 (es) | Nuevos conjugados de principios activos y proteinas. | |
GB1298980A (en) | An enzymatically active composition and a process for preparing it | |
DE69321131D1 (de) | Pharmazeutische zusammensetzung für ortsspezifische abgabe von blutgerinselauflösende proteine | |
KR930005636A (ko) | 크리오침전물(cryoprecipitate)을 사용하여 제조한 개량된 티슈 글루(tissue glue) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 675736 Country of ref document: ES |